Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16618965 | 0.73 | KCNK3 (0.36) | LMNASMN1; SMN2ALDH1A1KDM4EKCNK3 | |
| SCHEMBL16629549 | 0.68 | ALDH1A1 (0.41) | LMNAALDH1A1KDM4EHTR2AHTR2C | |
| SCHEMBL17968728 | 0.66 | MEN1 (0.49) | LMNASMN1; SMN2ALDH1A1KDM4EUSP2 | |
| SCHEMBL11611131 | 0.66 | MEN1 (0.63) | LMNASMN1; SMN2ALDH1A1PIK3CAPIK3CB | |
| SCHEMBL11606241 | 0.64 | ALDH1A1 (0.38) | LMNASMN1; SMN2ALDH1A1KDM4EPIK3CA | |
| SCHEMBL19960991 | 0.62 | PER2 (0.44) | SMN1; SMN2ALDH1A1KDM4EKCNK3PIK3CA | |
| SCHEMBL18202161 | 0.62 | PER2 (0.41) | SMN1; SMN2ALDH1A1KDM4EKCNK3HTR2A | |
| SCHEMBL15093911 | 0.62 | LMNA (0.66) | LMNASMN1; SMN2ALDH1A1KDM4EPIK3CA | |
| SCHEMBL3048743 | 0.62 | LMNA (0.66) | LMNASMN1; SMN2ALDH1A1KDM4EPOLB | |
| SCHEMBL18202353 | 0.62 | PER2 (0.40) | SMN1; SMN2ALDH1A1KDM4EKCNK3PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052495-B1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3052495-B1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
| EP-3052495-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049616-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015049616-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | LMNA 1064/4885SMN1; SMN2 1127/4885ALDH1A1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.